from concepts to biomarkers

& innovations in precision medicine

17 research teams,

9 platforms, 3 hosted biotechs

our state-of-the-art tools,

for cancer research

in the heart of a campus dedicated to applied cancer research...

...and Montpellier,

a city historically linked to medical research and teaching

the IRCM research teams
the IRCM research teams

L'Institut de Recherche en Cancérologie de Montpellier :
«Together, let's push the boundaries»

News

SEMINAIRE IRCM JEUDI 05 OCTOBRE 14h

Mutita JUNKING, PhDAssistant Professor Molecular Biology, Siriraj Hospital, Mahidol University (Thailand)Chimeric Antigen Receptor T Cells Targeting CD19 and Secreting Anti-PD-L1 Single Chain Variable Fragment Reduce PD-L1-induced T Cell Exhaustionhost: Emmanuel Cornillot (Montpellier University-IRCM) Dr. Mutita Junking is an Assistant Professor of Molecular Biology within theResearch Department at the Faculty of Medicine, Siriraj Hospital, MahidolUniversity. She also holds the position of Head of the Division of MolecularMedicine in the Research Department and is the Deputy Director of the SirirajCenter of Research Excellence for Cancer Immunotherapy (SiCORE-CIT).Her research focus on the advancing cellular immunotherapy for cancertreatment. Her research group has developed protocols and published data related to dendritic cell-induced anti-tumor T cells.They have also madesignificant strides in developing chimeric antigen receptor (CAR) T cellstargeting tumor-associated antigens across various cancer models, includinghematologic malignancies and solid tumors. Dr. Mutita is dedicated topushing the boundaries in CAR T cell research, aspiring to create the nextgeneration of CAR T cells that are not only more effective but also holdimmense potential for treating cancer patients. Résumé Séminaire :Adoptive T cell therapy utilizing second-generation anti-CD19 chimericantigen receptor (anti-CD19-CAR2) T cells has achieved completeremission in heavily pretreated patients with B cell acute lymphoblasticleukemia (B-ALL) or diffuse large B cell lymphoma (DLBCL). However, theclinical efficacy in aggressive B cell lymphomas (BCL) has been suboptimaldue to programmed cell death protein 1 ligand (PD-L1) expressed on BCLcells binding to the PD-1 receptor on T cells, leading to limited T cellfunction. We designed and generated anti-CD19-CAR4-T cells that secreteanti-PD-L1 single-chain variable fragment (scFv), referred to as anti-CD19-CAR5-T cells. Both anti-CD19-CAR-T cell types feature an anti-CD19 scFvderived from monoclonal antibody, coupled with CD28/4-1BB/CD27/CD3ζf or enh anced f unc tion alit y. The ant i-PD-L1 scFv o rig in at es fromatezolizumab and demonstrated the ability to bind to PD-L1, inhibiting thebinding of anti-PD-L1 monoclonal antibodies to PD-L1high cancer cells. Invitro evaluations showed that both anti-CD19-CAR4-T and anti-CD19-CAR5-T cells efficiently targeted and killed CD19+ cancer cells in 2D and3D co-culture systems. Interestingly, anti-CD19-CAR5-T cells displayedsuperior proliferative capacity. At a low effector (E) to target (T) ratio of0.5:1, anti-CD19-CAR5-T cells exhibited higher cytotoxicity againstCD19+/PD-L1high cells compared to anti-CD19-CAR4-T cells. Notably, thecytotoxicity of anti-CD19-CAR4-T cells against CD19+/PD-L1high cells couldbe restored by supplementing anti-PD-L1 scFv. Our findings highlight thepromising combination antitumor efficacy of anti-CD19-CAR4-T cells andanti-PD-L1 scFv against CD19+/PD-L1high tumors. As a result, anti-CD19-CAR5-T cells warrant further investigation in terms of in vivo antitumorefficiency and potential inclusion in clinical trials as a treatment foraggressive B cell lymphoma.  
En savoir plus

SEMINAIRE VENDREDI 29 SEPTEMBRE A 14h

Jonathan RebouletLiPiCS Services (Lyon-France)"Application of a  new protein-protein interactions screening technology to decipher oncoprotein interactomes and their alterations by mutations, drugs and peptides."contact : Eric JULIEN (CNRS/Inserm)Protein-protein interactions are a key factor to understand a protein function. As we tried to identify molecular mechanisms explaining the pro and anti-tumoral effect of a well known transcription family, we developped a Bimolecular Fluorescence Complementation based asssay to screen in live cell line for whole interactome of a target. Reaching higher robustness than other screening technology, we performed comparative analysis to understand the effect of differents effectors and mutations on target interactome.
En savoir plus

L'IRCM - Institut de Recherche en Cancérologie de Montpellier a accueilli depuis hier le 10ème Symposium International sur les électrons Auger (https://lnkd.in/duGuch6Z), regroupant une communauté de physiciens, radiobiologistes, chimistes et médecins nuc

L'IRCM - Institut de Recherche en Cancérologie de Montpellier a accueilli depuis hier le 10ème Symposium International sur les électrons Auger (https://lnkd.in/duGuch6Z), regroupant une communauté de physiciens, radiobiologistes, chimistes et médecins nucléaires. 2023 correspond au centenaire de la découverte de ces électrons par Pierre Auger.Pierre Auger est un brillant physicien qui, outre ses travaux de recherche sur les électrons de basse énergie, a contribué au développement des grandes institutions nationales (CEA avec Frédéric Joliot et Francis Perrin) et internationales telles que le CERN, le CNES, le CIC (Centre Internationale de Calcul) ou l'UNESCO.Jean-Pierre Pouget (Pouget Lab (Jean-Pierre Pouget)) a pu organiser, pour la première fois, cette conférence en France (avec Raymond Reilly, Université de Toronto) pour cette occasion.Outre les excellentes présentations de scientifiques venus de tout horizon (Europe, USA, Afrique du Sud, Japon, Australie, Taïwan, etc.), une session historique a été animée par des historiens et des experts scientifiques pour discuter de la paternité de cette découverte qui était sujet à discussion depuis quelques années! A l'unanimité, le groupe d'experts a attribué la découverte de ces électrons à Pierre Auger. Le débat est donc clos. Un succès!Un grand merci aux sponsors : SIRIC Montpellier, ICM - Institut du Cancer de Montpellier, MILabs, Oncodesign Services, PRISMAP Project  le site officiel : https://auger-symposium.com/ 
En savoir plus

SEMINAIRE VENDREDI 10 NOVEMBRE 14h

Elodie LALLETINTEGRAGEN, Genopole Campus, Evry (Paris)"Innovation en analyses et tests Génomiques : nouvelles avancées en oncologie"contact : Pierre-François ROUX (equipe L. LeCam-INSERM)
En savoir plus

10ème symposium international sur les aspects physiques, moléculaires, cellulaires et médicaux des processus d'électrons Auger : du 6 au 8 septembre 2023

Rejoignez-nous au 10ème symposium international sur les aspects physiques, moléculaires, cellulaires et médicaux des processus d'électrons Auger à l'Institut de Recherche en Cancérologie de Montpellier (France) du 6 au 8 septembre 2023 ! Inscription sur : http://auger-symposium.com
En savoir plus

Nos salariés mobilisés pour la recherche contre le cancer

Nos salariés mobilisés pour la recherche contre le cancer Les liposarcomes sont des tumeurs rares dont le diagnostic par biopsie est long et difficile. L’équipe de recherche de Laetitia Linares, en étroite collaboration avec le Dr Nelly Firmin, oncologue en charge des sarcomes à l’ICM, a développé un nouveau test diagnostic à partir d’une simple prise de sang.  Un essai clinique est actuellement en cours sur une centaine de patients pour évaluer la robustesse de ce test. Les salariés de l’ICM et de l’IRCM, engagés et volontaires, se sont dévoués pour être les contrôles sains de cette étude. Merci à eux pour leur engagement. 
En savoir plus

the word of the director

"Together, let's push the limits."

"In barely 20 years, the Institut de Recherche en Cancérologie de Montpellier (IRCM U1194) has succeeded in raising its research to the highest international level in the field of fundamental and applied cancer research, carried out in close collaboration with the clinical departments of the Montpellier Cancer Center (ICM: l'Institut du Cancer de Montpellier), and industrial partners. Under the joint supervision of Inserm, the ICM and the University of Montpellier, the IRCM brings together more than 240 people, researchers, clinicians, technicians and students, organized in 16 research teams that rely on high-performance technical platforms and competent support services. In an extremely competitive and rapidly evolving field of research, our greatest challenge is to stay one step ahead. To do so, we will continue to structure cancer research in Montpellier, to seek excellence and to accelerate innovation and transfer to the patient in order to ultimately contribute to overcoming the countless different forms of cancer. Together, let's push the limits"

Nathalie Bonnefoy, Director of the IRCM

the word of the director

MAIN PUBLICATIONS

Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol J-L, Calvayrac O, Moll H, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong K-K, Yarden Y, Casanova E, Soria J-C, Colinge J, Siebel C, Favre G, Paz-Ares L, Maraver A Notch inhibition overcomes resistance to Tyrosine Kinase Inhibitors in EGFR-driven lung adenocarcinoma. J. Clin. Invest.. Oct 31, 2019. doi:10.1172/JCI126896

Combes E, Andrade A, Tosi D, Michaud H-A, Coquel F, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Martineau P, Del Rio M, Beijersbergen R, Vezzio-Vie N Inhibition of Ataxia-Telangiectasia Mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes anti-tumor immunity in colorectal cancer. Cancer Res.. Apr 15, 2019. doi:10.1158/0008-5472.CAN-18-2807

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z

Ladjohounlou R, Lozza C, Pichard A, Constanzo J, Karam J, Le Fur P, Deshayes E, Boudousq V, Paillas S, Busson M, Le Blay M, Jarlier M, Marcatili S, Bardiès M, Bruchertseifer F, Morgenstern A, Torgue J, Navarro-Teulon I, Pouget J-P Drugs that modify cholesterol metabolism alter the p38/JNK-mediated targeted and non-targeted response to alpha and Auger radioimmunotherapy. Clin. Cancer Res.. May 06, 2019. doi:10.1158/1078-0432.CCR-18-3295

Perrot I, Michaud H-A, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou J-F, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. Cell Rep. 2019;27(8):2411-2425.e9. doi:10.1016/j.celrep.2019.04.091

Forest E, Logeay R, Géminard C, Kantar D, Frayssinoux F, Heron-Milhavet L, Djiane A The apical scaffold big bang binds to spectrins and regulates the growth of Drosophila melanogaster wing discs. J. Cell Biol.. 2018;217(3):1047-1062. doi:10.1083/jcb.201705107

Arena G, Cissé M, Pyrdziak S, Chatre L, Riscal R, Fuentes M, Arnold J, Kastner M, Gayte L, Bertrand-Gaday C, Nay K, Angebault-Prouteau C, Murray K, Chabi B, Koechlin-Ramonatxo C, Orsetti B, Vincent C, Marine J-C, Etienne-Manneville S, Bernex F, Lombès A, Cameron C, Dubouchaud H, Ricchetti M, Linares L, Le Cam L Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53. Mol. Cell. 2018;69(4):594-609.e8. doi:10.1016/j.molcel.2018.01.023

Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet J-M, Pèlegrin A, Larbouret C, Robert B Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clin. Cancer Res.. 2017;23(11):2806-2816. doi:10.1158/1078-0432.CCR-16-1316


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés